Equities research analysts predict that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will announce earnings of ($0.31) per share for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for BioCryst Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.34). BioCryst Pharmaceuticals posted earnings per share of ($0.19) during the same quarter last year, which would indicate a negative year over year growth rate of 63.2%. The business is expected to report its next quarterly earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full year earnings of ($1.21) per share for the current fiscal year, with EPS estimates ranging from ($1.27) to ($1.14). For the next financial year, analysts expect that the company will report earnings of ($0.99) per share, with EPS estimates ranging from ($1.35) to ($0.69). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.28) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.28). BioCryst Pharmaceuticals had a negative return on equity of 223.34% and a negative net margin of 472.12%. The business had revenue of $5.89 million for the quarter, compared to analysts’ expectations of $2.92 million.
In related news, insider Thomas R. Staab II sold 7,500 shares of the stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $8.81, for a total value of $66,075.00. Following the completion of the sale, the insider now directly owns 140,176 shares of the company’s stock, valued at approximately $1,234,950.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Thomas R. Staab II sold 9,000 shares of the stock in a transaction on Monday, May 6th. The shares were sold at an average price of $7.75, for a total value of $69,750.00. Following the completion of the sale, the chief financial officer now directly owns 140,426 shares of the company’s stock, valued at $1,088,301.50. The disclosure for this sale can be found here. Insiders sold a total of 75,000 shares of company stock valued at $583,298 over the last three months. 5.20% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCRX. RA Capital Management LLC raised its holdings in BioCryst Pharmaceuticals by 15.4% during the fourth quarter. RA Capital Management LLC now owns 10,660,349 shares of the biotechnology company’s stock worth $86,029,000 after purchasing an additional 1,425,657 shares in the last quarter. FMR LLC boosted its position in shares of BioCryst Pharmaceuticals by 15.9% during the first quarter. FMR LLC now owns 3,467,998 shares of the biotechnology company’s stock valued at $28,229,000 after purchasing an additional 475,989 shares in the last quarter. Federated Investors Inc. PA boosted its position in shares of BioCryst Pharmaceuticals by 78.7% during the first quarter. Federated Investors Inc. PA now owns 779,406 shares of the biotechnology company’s stock valued at $6,344,000 after purchasing an additional 343,269 shares in the last quarter. Emory University purchased a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth $2,564,000. Finally, Bank of New York Mellon Corp raised its stake in shares of BioCryst Pharmaceuticals by 29.0% in the fourth quarter. Bank of New York Mellon Corp now owns 543,026 shares of the biotechnology company’s stock worth $4,383,000 after purchasing an additional 122,201 shares during the last quarter. 91.98% of the stock is owned by institutional investors and hedge funds.
BCRX stock traded down $0.10 during trading on Wednesday, hitting $3.52. The company had a trading volume of 37,102 shares, compared to its average volume of 2,804,299. The stock has a 50-day moving average price of $4.66. BioCryst Pharmaceuticals has a one year low of $2.80 and a one year high of $9.95. The firm has a market cap of $399.32 million, a PE ratio of -3.61 and a beta of 2.14. The company has a debt-to-equity ratio of 2.38, a quick ratio of 1.76 and a current ratio of 1.77.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
Featured Story: What is a Real Estate Investment Trust (REIT)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.